Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Nimotuzumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms NOTABLE-309
- Sponsors Biotech Pharmaceutical
- 22 Jan 2025 New trial record